112TiP SOLTI-1710 PROMETEO II: Palbociclib in combination with letrozole in patients with hormone receptor-positive (HR+)/HER2-negative residual disease after standard neoadjuvant chemotherapy (NAC)

Abstract

Despite the improvement in the treatment of early-stage breast cancer (BC) with chemotherapy, many patients have residual disease with a higher risk of metastatic recurrence and poorer outcome than those who achieve a pathological complete response (pCR), particularly in highly proliferative tumors. In HR+ BC, the pCR rates after NAC are around 10-15%. Additional therapeutic strategies to eradicate these residual tumor cells are needed. The combination of cyclin-dependent kinase inhibitors with first or second-line endocrine therapy are options for metastatic BC and its role in the early-setting is being evaluated in several studies.